Figure 5.

Sorafenib and the MEK inhibitor AZD6244 co-formulated in CTCE9908-NPs suppress angiogenesis in the fibrotic livers of CCl₄-treated mice. A, Representative confocal images of vWF staining in the fibrotic livers from mice treated with different formulations (scale bar=100 μm). B-C, Sorafenib and AZD6244, delivered by CTCE9908-NPs, significantly reduced the microvascular density (B) and decreased the mean vessel diameter (C) in fibrotic livers from CCl₄-treated mice, as observed by staining for vWF (n=10-26). The data are presented as mean values ± S.E.M., **p<0.01 and ***p<0.001.